FDA violations rampant in CBD retail marketing across America

A comprehensive analysis of CBD advertising at retail locations across three U.S. states reveals widespread regulatory violations. Researchers systematically examined 1,090 CBD-specific advertisements in 150 retailers across Colorado, Maryland, and North Carolina between November 2021 and April 2022. The findings are striking: over 61.8% of CBD advertisements contained at least one prohibited claim under FDA regulations, totaling 985 violations across all claim types. This represents a systematic failure of retailers to comply with existing federal guidelines designed to protect consumer safety and prevent misleading marketing practices.

The violations fell into predictable categories that directly mislead consumers about what CBD can actually do. 53.6% of ads illegally marketed CBD as an unapproved pharmaceutical drug, while 51.6% marketed it as a food additive or food product—both prohibited by the FDA. The research documented prohibited therapeutic claims for 125 different health conditions, ranging from pain and inflammation to cancer and other serious diseases. Most troubling, 80% of retailers displayed at least one prohibited claim, indicating this is not an isolated problem but a systemic issue across the cannabis retail market. These findings highlight a critical gap between FDA regulations and actual market practices, leaving consumers vulnerable to misleading health claims without sufficient enforcement mechanisms.

The study underscores the urgent need for regulatory enforcement and consumer protection in the rapidly growing CBD market. Without intervention, consumers may make purchasing decisions based on false or unproven health claims, wasting money on products that don't deliver promised benefits or potentially delaying proper medical treatment for serious conditions. The consistency of violations across different state regulatory environments suggests that the problem is national in scope, not confined to particular jurisdictions. This research provides concrete evidence that the FDA and state regulators must strengthen oversight of CBD marketing to ensure public health protection.